Athira Pharma Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
/ 
Others were interested in
Frequently asked questions
To buy Athira Pharma Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Athira Pharma Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Athira Pharma Inc. is ATHA:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Athira Pharma Inc. has its primary listing on NASDAQ. You can trade Athira Pharma Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Athira Pharma Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Athira Pharma Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Athira Pharma Inc..